Nemluvio

Galderma's tariff hedge costs about 6% of its U.S. sales a year

A $650m manufacturing commitment through 2030 comes to roughly $130m a year against $2.1bn of American revenue, which is cheap enough that the more consequential move is the one Galderma made to its org chart.